Compare Trip.com Group Ltd (TCOM) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Trip.com Group Ltd vs TG Therapeutics Inc — how do they compare? Trip.com Group Ltd trades at $44.07 (market cap $28.12B), while TG Therapeutics Inc trades at $54.5 (market cap $8.26B). The key difference: Trip.com Group Ltd is far larger — about 3.4× TG Therapeutics Inc's market cap, and Trip.com Group Ltd pays a 0.42% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| TCOM | TGTX | |
|---|---|---|
Market Cap | $28.12B | $8.26B |
Sector | Consumer Cyclical | Health |
52-Week High | $78.96 | $59.06 |
52-Week Low | $39.84 | $26.39 |
Enterprise Value | $20.82B | $8.50B |
Dividend Yield | 0.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TCOM trades at $44.15, up 4.0% over 24 hours but facing near-term pressure after recent earnings misses and regulatory scrutiny. The stock shows strong fundamentals with a P/E of 6.38 and net income margin of 48.65%, supported by robust revenue growth from $20.0B in 2022 to $62.4B in 2025. Technical indicators signal a bearish trend with resistance at $44-$45, while analyst consensus remains bullish with a $56.72 price target despite recent guidance concerns.
The outlook balances high profitability and undervaluation against regulatory risks and slowing growth guidance. Investment appeal lies in its dominant market position and cash flow strength, but investors face headwinds from antitrust investigations and margin pressure. The stock's current discount to analyst targets presents opportunity if execution improves.
TG Therapeutics (TGTX) trades at $53.96, down 1.6% on the day, with mixed technical signals showing a neutral overall trend. The company demonstrates strong profitability with 65.95% net income margin and 112.6% ROE, though recent earnings have missed expectations in two of the last three quarters. Positive clinical developments for Briumvi in multiple sclerosis and schizophrenia trials provide growth catalysts, while a shareholder investigation presents near-term uncertainty.
The outlook remains cautiously optimistic with 84.6% analyst buy ratings but a consensus price target of $48.50 below current levels. Key opportunities include Briumvi's expanding indications and strong revenue growth, while risks involve clinical trial outcomes, the ongoing legal investigation, and premium valuations with P/E of 19.2 and P/S of 12.6.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Trip.com Group Ltd
Trip.com is the largest online travel agent in China and is positioned to benefit from the country's rising demand for higher-margin outbound travel as passport penetration is only 12% in China. The company generated about 78% of sales from accommodation reservations and transportation ticketing in 2020. The rest of revenue comes from package tours and corporate travel. Prior to the pandemic in 2019, the company generated 25% of revenue from international business, which is important to its margin expansion. Most of sales come from websites and mobile platforms, while the rest come from call centers. The competes in a crowded OTA industry in China, including Meituan, Alibaba-backed Fliggy, Toncheng, and Qunar. The company was founded in 1999 and listed on the Nasdaq in December 2003.
Read more on TCOM →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
